company. Chris. our much Thank you permanent and CEO four first little a as Interim for since over has very It I been months the in the stepped then CEO as
board me offered have people asked I appointment why me it to decided the in when many So accept to permanent May.
in prospects always by its the and understand diagnostic bring the MosaiQ the short the so to hard past wider potential right field. that at multiplexing the so market. it the I based personal. in market Quotient for the became been have I got So of people place also microarray set to know course know and the answer that and better auto is and of long to fascinated of to work technology
not could company to the to resist its potential. close team help I achieving to So bring that vision, saw this how full it the when I challenge realized full
experience do complementary the have it I I to done. help to thought, skills team think and I and yes, let's get it
that technology. [ph] So many it has the makes this B-chat for as the transfusion initial diagnostics the characteristics, team selected, market which
As by of our in of video, demand They every innovation. and platforms their compounded the to last our participated quote said Investor true said, market by an population the which when of they end here have prospective via a for increasing month in laboratories ageing recent “the is characterized need I due lack manual also having testing” and quote. instrument lot a customers perform complexity their and multiple is to Day
customer? at work that and came point asked of our buy actually to of year will us us. it hands the answer single questions the help from needs field which I The the to remainder features this results. my more sample. EU unmet yet will first it? is third a factors the of technology shortage is customers when the they've and have many second Well, what customers question. all very well the our my in volume combined approve of of of myself MosaiQ. potential I with heard the When question, that of from recent answered technicians, But capabilities we for is is lastly on three questions, trial about respect most with aligned will submission, the development of CE solution ever we've three Will this Mark our initial foundation delivering to flow I with comprehensive old these characterization our So believe truly fully critical catalysts blood automated use an trained blood behind for risk regulators the low board
to focus my too many taking after we on any and simply to should inputs requires take sequential successful development. to key In of being with things a my of parallel were past This one trying the responsibilities them. that we ensure in So success. CEO approach not was very
after priorities get Expectations report were IH which to the my permit the completed were concoction the I set and has We move Microarray was field three a The the subsequently validation and with trail result and on trial field then the first VNB process line expectation. timelines, and initial the completing to verification and ender European focused as we us of the to in able trial. team we field state set arrival. to
is because this we on have initial in microarray it development, last Serological Microarray, commencing very trial it, the verification very Today's entered will completed is validation we the European microarray Now, field SDS demonstrate market. that our operating critical large of the important the phase for Disease the is and once announcement before our step focus important. diagnostic this key technology
for So are Quotient. be very time the nine next to six to exciting shaping months up
initial expect the with can their Microarray offering if our Mark be management evaluation devices they CE will place own we change IH and planning we to process for to so XXXX. able submit of Firstly, successful, begin customers, and during
the needs initial the Secondly, in we demonstrate specificity multiplex hope our a trial screening market. disease field SDS and to hands potential of sensitivity with format of to the meet Microarray, customers the in required the of with
lastly, make we technology clinically to transfusion expand will Microarray diagnostic tell XX IH initial that that donor And this. market. our antigens an MosaiQ status in plan do must the we actually encompass us internal successfully to the additional have can relevant Our
developing we're we these we on each disciplined our outcome of deliver to to strong, of collaborative successful to a execution projects. everything ensure and a goals can So the approach sequential do development
be we review. everything about regulatory ensure no that guarantees of outcome can any while we're success, the doing course, there to Of can
up warrants last connection shares on of placement of executed our more our our of in last We the and also on portion made October. good the fronts second exercise elements with successfully private We've drawdown the of outstanding senior since funding note the with progress other two key long-term the conference of recently facility issuance call. sold
million roughly So totaled to last the we company cash the flows in $XX two months. of
grow continues growth as location recording business in OEM original the to as our for addition, newly even and from in In well in direct digit revenues typing robustly as business base constructed its both lines the to double transition managed our facility. blood record reagent strong a liquid Biocampus
So I feel progress and team is very making prospects future. our about the positive about for the our
So with that Chris? let Chris to Lindop, CFO. me hand the call over our
